Lymph node dissection, the standard surgical treatment for melanoma, does not increase patient survival rates, according to a study published in The New England Journal of Medicine. Lymph node ...

Mitotic rate ≥1/mm² and residual tumor presence are linked to higher relapse risk in cutaneous melanoma patients post-excision. Lymphovascular invasion significantly correlates with worse relapse-free ...

Iovance Biotherapeutics announced positive five-year results from its Phase 2 C-144-01 clinical trial for Amtagvi® (lifileucel), a T cell therapy for advanced melanoma patients who previously received ...

Iovance Biotherapeutics, Inc. announced promising five-year follow-up results from the Phase 2 C-144-01 clinical trial of their T cell therapy Amtagvi® (lifileucel) for advanced melanoma. Published in ...